# Sunshine Biopharma Inc. (SBFM) · Edgar & Edgarette company card

> Sunshine Biopharma (SBFM) grew revenue 4.1% in FY2025 to $36 million, operating margin -17.2% against a -3.8% median for pharmaceutical preparations, equity 76.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1402328 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SBFM) · [JSON](https://www.pops4.com/boards/company/SBFM.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $36M |
| Revenue growth, 1 year | 4.1% |
| Revenue growth per year | 255.1% |
| Operating margin | -17.2% (prior year -16.7%) |
| Net margin | -16.5% |
| Operating cash flow | −$5M |
| Capital spending | $174,491 |
| Free cash flow | −$6M |
| Cash | $9M |
| Long-term debt | — |
| Total assets | $30M |
| Total equity | $23M |
| Equity ÷ assets | 76.6% |
| Return on equity | -25.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -1.63 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice in the last 12 months; operating cash flow was negative; operating loss: a margin of -17.2% in FY2025; revenue is hard to predict: its 80% range is ±72%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $36.3M (FY2025). Experience: revenue up 4.1% on the year, up 255.1% a year over 4 years; operating margin -17.2%, down from -16.7%. Soundness: equity 76.6% of assets, return on equity -25.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $22.2M and $136.4M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $19.6M to $155.1M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -17.2% against a -3.8% median; growth 4.1% against 13.7%.

Range logged 2026-09-25, receipt 528a437236d15f0d, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002539/0001683168-26-002539-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-08-28 ([filing](https://www.sec.gov/Archives/edgar/data/1402328/000168316826006777/0001683168-26-006777-index.htm))

## Recent filings

- 8-K · filed 2026-10-14 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007845/0001683168-26-007845-index.htm)
- 8-K · filed 2026-10-09 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007758/0001683168-26-007758-index.htm)
- S-1 · filed 2026-10-02 · [filing](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007581/0001683168-26-007581-index.htm)
- 8-K · filed 2026-09-16 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007193/0001683168-26-007193-index.htm)
- 8-K · filed 2026-09-11 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007090/0001683168-26-007090-index.htm)
- S-1 · filed 2026-08-28 · [filing](https://www.sec.gov/Archives/edgar/data/1402328/000168316826006779/0001683168-26-006779-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001402328.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1402328

## Cite

POPS4, Edgar & Edgarette: Sunshine Biopharma Inc. (SBFM) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/SBFM. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.